Nanoconfinement-mediated cancer theranostics

Arch Pharm Res. 2020 Jan;43(1):110-117. doi: 10.1007/s12272-020-01217-2. Epub 2020 Jan 27.

Abstract

Despite various therapeutic or diagnostic developments, cancer is still one of the most lethal diseases due to insufficiently adequate treatments and the delay of the early stage of disease detection. An image-guided drug delivery system (IGDDS), as a real-time noninvasive imaging assessment of therapeutic response, has the strong potential to improve the diagnosis and treatment of cancer because its imaging property offers the quantification of nanomedicine at the intended disease sites, the possible assurance of adequate treatment and elimination of undesirable delay of early-stage diagnosis due to low resolution. One of potential modality that overcomes these challenges could be the nanoconfinement of gold (Au) nanoparticles within other nanoparticles called "Particle-in-Particle (PIP)", which is a strong candidate of cancer treatment because of its "theranostic (therapy + diagnostics)" advantages including imaging (e.g., CT) and therapeutic hyperthermia application. In this review, we will elaborate on the current application of theranostic by nanoconfinement. Then, we will narrow down the gold nanoparticle-mediated theranostic application and its nanoconfinement advantages. Finally, the future direction for maximum nanoconfinement mediated cancer therapy will be included.

Keywords: Nanoconfinement; Particle-in-Particle; Theranostics.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems
  • Gold / chemistry*
  • Humans
  • Metal Nanoparticles / chemistry*
  • Neoplasms / diagnostic imaging*
  • Neoplasms / drug therapy*
  • Theranostic Nanomedicine*

Substances

  • Gold